Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Enters Into New $1B Revolving Credit Facility

NEW YORK (GenomeWeb) – Danaher last week entered into a new $1.0 billion 364-day revolving credit facility, the firm disclosed after the close of the market on Monday.

In a document filed with the US Securities and Exchange Commission, the company said that it entered into the facility with Bank of America, as the administrative agent, and a syndicate of lenders.

The credit facility expires on March 22, 2019. Danaher may elect to convert any loans outstanding on the schedule termination date into loans that are due and payable one year following the scheduled termination date. If it does so, it will pay a fee of .75 percent of the principal amount of the loans then outstanding.

Danaher said it intends to use the credit facility to expand its US and European commercial paper programs and for corporate purposes, and to fund a portion of its planned purchase of Integrated DNA Technologies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.